TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03488316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carie removal
Description: Carie removal with a low speed handpiece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carie removal
Description: Carie removal with a low speed handpiece

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation
Description: Absolute isolation with rubber dam

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation
Description: Absolute isolation with rubber dam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary filling material based on Calcium Hydroxide
Description: Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the temporary filling material based on Mineral trioxide aggregate
Description: Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material insertion on the root canal
Description: Material insertion on the root canal according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material insertion on the root canal
Description: Material insertion on the root canal according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material re-insertion on the root canal accordging to the infection needs.
Description: Material re-insertion on the root canal according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Material re-insertion on the root canal accordging to the infection needs.
Description: Material re-insertion on the root canal according to the manufacturer's recommendations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definiteve canal root obturation
Description: Definiteve canal root obturation with gutta-percha and definitive cement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definiteve canal root obturation
Description: Definiteve canal root obturation with gutta-percha and definitive cement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitve restoration
Description: Definitve restoration confecction.
Study: NCT03521479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Study: NCT03488316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definitve restoration
Description: Definitve restoration confecction.
Study: NCT00891358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Empowerment Intervention for Young Women
Description: Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs.
Study: NCT03240133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: oral liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: oral liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: oral liquid formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral liquid formulation to match BCX7353
Study: NCT00469482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation,RASS Targeted plus BIS Monitoring
Description: Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation, RASS Targeted
Description: Patient sedation utilizing standard of care methods (RASS targeted)
Study: NCT03239470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 1: 1.0 x 10^8 PolyTregs
Description: Each participant will receive a target cell dose of 1.0 x 10\^8 polyclonal Tregs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort 2: 2.5x10^8 PolyTregs
Description: Each participant will receive a target cell dose of 2.5x10\^8 polyclonal Tregs.
Study: NCT02755376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cartistem(TM)
Description: ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: ACL reconstruction and injection of hyaluronic acid under arthroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction only
Description: ACL reconstruction only without any injection under arthroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction only
Description: ACL reconstruction only without any injection under arthroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction only
Description: ACL reconstruction only without any injection under arthroscopy
Study: NCT02511470

Intervention type: OTHER
Group type: OTHER
Intervention: Metronome on
Description: Metronome on during participants performance of CPR on a pediatric manikin

Intervention type: OTHER
Group type: OTHER
Intervention: Metronome off
Description: Metronome off during participants performance of CPR on a pediatric manikin
Study: NCT01510119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT03721419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow High Humidity device
Description: High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow High Humidity device
Description: Standard high humidity trach collar utilizing venturi device bleed in
Study: NCT03521479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Study: NCT01023581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules.
Study: NCT01748253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan-amlodipine tablet administration group (morning)
Description: Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan-amlodipine tablet administration group (bedtime)
Description: Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
Study: NCT00922766

Intervention type: DRUG
Intervention: Dalteparin
Description: Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
Study: NCT02603432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Following the planned interim analysis for this study: Avelumab
Description: 1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
Study: NCT01982955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
Study: NCT03071172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Soft Capsules
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study: NCT05843526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental healing abutment
Description: Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment
Study: NCT00803881

Intervention type: OTHER
Intervention: nasal lavage and sputum collection
Description: non-invasive longitudinal assessment of pathogen colonization in both airway levels
Study: NCT04760158

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
Study: NCT03521479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Squaric Acid Dibutyl Ester
Description: Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
Study: NCT01982955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Study: NCT04760158

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
Study: NCT01735656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute stents
Description: zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute stents
Description: zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
Study: NCT01903304

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 3 months intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: 3 months intervention
Study: NCT03592433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can PIC
Description: Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
Study: NCT02189564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback about good performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about good performance + money

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about average performance
Study: NCT04145895

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative activity restrictions
Description: Recommendations for return to full activity including return to school, sports, exercise, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative activity restrictions
Description: Recommendations for return to full activity including return to school, sports, exercise, etc.
Study: NCT00889954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFBeta resistant HER2/EBV-CTLs
Description: Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals.
Study: NCT04287504

Intervention type: DIAGNOSTIC_TEST
Intervention: SavvyCheck Vaginal Yeast Test
Description: Point-of-care test for the detection of vaginal candidosis

Intervention type: DIAGNOSTIC_TEST
Intervention: SavvyCheck Vaginal Yeast Test
Description: Point-of-care test for the detection of vaginal candidosis

Intervention type: DIAGNOSTIC_TEST
Intervention: OSOM BVBLUE Test
Description: Point-of-care test for the detection of bacterial vaginosis

Intervention type: DIAGNOSTIC_TEST
Intervention: OSOM BVBLUE Test
Description: Point-of-care test for the detection of bacterial vaginosis
Study: NCT03442738

Intervention type: PROCEDURE
Intervention: Endocuff group
Description: Endocuff Vision cap on Standard colonoscope

Intervention type: PROCEDURE
Intervention: Endocuff group
Description: Endocuff Vision cap on Standard colonoscope
Study: NCT00116831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: oral anti-diabetic medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: oral antidiabetic medication
Study: NCT04279665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: 20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
Study: NCT01623869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT00099866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Comparator
Study: NCT01868334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 1: Convenient Vaccination Services
Description: Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 2: Patient notification
Description: Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 3: Enhanced Office Systems
Description: Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 4: Motivation
Description: Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
Study: NCT03616912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT04651127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + Chidamide
Description: In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
Study: NCT04373746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICCI
Description: Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICCI
Description: Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
Study: NCT03869879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback-assisted physical therapy
Description: The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional physical therapy
Description: Therapists will treat these patients with traditional therapeutic modalities and practices.
Study: NCT02547584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care